NASDAQ:TRIB Trinity Biotech Q2 2026 Earnings Report $9.71 -0.62 (-6.00%) Closing price 04:00 PM EasternExtended Trading$9.72 +0.01 (+0.06%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Trinity Biotech EPS ResultsActual EPSN/AConsensus EPS -$7.80Beat/MissN/AOne Year Ago EPSN/ATrinity Biotech Revenue ResultsActual RevenueN/AExpected Revenue$10.31 millionBeat/MissN/AYoY Revenue GrowthN/ATrinity Biotech Announcement DetailsQuarterQ2 2026Date9/3/2026TimeN/AConference Call DateFriday, September 4, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Trinity Biotech Earnings HeadlinesTrinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI InfrastructureAugust 17, 2026 | finance.yahoo.comTrinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI InfrastructureAugust 17, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.August 25 at 1:00 AM | InvestorPlace (Ad)Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price RequirementAugust 14, 2026 | globenewswire.comTrinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ TechnologyJuly 22, 2026 | finanznachrichten.deTrinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ TechnologyJuly 22, 2026 | globenewswire.comSee More Trinity Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Trinity Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trinity Biotech and other key companies, straight to your email. Email Address About Trinity BiotechTrinity Biotech (NASDAQ:TRIB) is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments. The company’s product portfolio includes a comprehensive array of assays and instrumentation. In the diabetes segment, Trinity Biotech provides hemoglobin A1c analyzers and glucose monitoring systems. It also offers serological and rapid tests for celiac disease, immunoassays for infectious diseases such as HIV and hepatitis B and C, and assays targeting cardiovascular risk markers. These products are used by hospitals, reference labs and clinics to support diagnosis, treatment monitoring and epidemiological surveillance. Trinity Biotech serves a worldwide customer base through direct sales operations in North America and Europe, together with a network of distributors in Asia Pacific, Latin America and the Middle East. Its manufacturing sites operate under internationally recognized quality standards, ensuring regulatory compliance across multiple jurisdictions. The company’s global footprint and supply chain infrastructure enable it to respond to regional healthcare needs efficiently. Supported by an experienced leadership team, Trinity Biotech maintains collaborations with research institutions and healthcare providers to drive innovation in diagnostic testing. Ongoing investment in product development and strategic partnerships underpins the company’s commitment to addressing emerging healthcare challenges and improving patient outcomes around the world.View Trinity Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DICK's Sporting Goods Faces Pain Now for a Bigger PrizeStoneX: Too Far Too Fast?Pathward’s Credit Scare Tests Its Comeback StoryNVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to WatchBeyond Big Tech: 3 Non-Tech Earnings Winners to WatchThe Bull Case for D-Wave After a Disappointing Earnings SeasonVisa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Upcoming Earnings Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
